Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vaccine adjuvant of swine mycoplasmal pneumonia live vaccine, and preparation method and application thereof

A technology for mycoplasma pneumonia and vaccine adjuvants, which is applied in the direction of medical preparations containing active ingredients, pharmaceutical formulas, bacterial antigen components, etc., can solve the high requirements of stability and preparation process, and the water-in-oil adjuvants are not Application and other issues

Active Publication Date: 2012-11-28
JIANGSU ACAD OF AGRI SCI
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This type of adjuvant usually has a good immune enhancement effect, but due to the damage of oil substances to the cell membrane, for attenuated live vaccines, water-in-oil adjuvants are not suitable, and even oil-in-water adjuvants are not suitable for Its stability and preparation process requirements are also very high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine adjuvant of swine mycoplasmal pneumonia live vaccine, and preparation method and application thereof
  • Vaccine adjuvant of swine mycoplasmal pneumonia live vaccine, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1 Toxicity Detection of Different Adjuvant Components to Live Vaccine of Mycoplasma Porcine Pneumonia

[0026] 1. Experimental materials

[0027] 1. Vaccine: Mycoplasma swine pneumonia (168 strains) live vaccine, provided by Nanjing Tianbang Biotechnology Co., Ltd.;

[0028] 2. Adjuvant ingredients: astragalus polysaccharide (purchased from Shaanxi Jintai Bioengineering Co., Ltd.); levamisole hydrochloride injection (purchased from Jiangsu Huadong Bell Biopharmaceutical Co., Ltd.); ISCOM matrix (made in the laboratory).

[0029] 2. Experimental method:

[0030] Various different adjuvant components were prepared into solutions of certain concentrations with phosphate buffer solution, and the concentrations of various adjuvant components were as follows:

[0031] Astragalus polysaccharide: 200mg / ml

[0032] Levamisole: 25mg / ml

[0033] ISCOM matrix: 5mg / ml (concentration of Quil A component contained)

[0034] Above-mentioned three kinds of adjuvant solution...

Embodiment 2

[0037]Embodiment 2 is applicable to the adjuvant and preparation thereof of porcine mycoplasma pneumonia live vaccine

[0038] The vaccine adjuvant of the swine mycoplasma pneumonia live vaccine of the present invention is characterized in that the adjuvant solution contains ISCOM matrix, levamisole, Chinese herbal medicine polysaccharide and phosphate buffer solution, and each ml solution of the adjuvant contains: ISCOM matrix 0.1-2mg of QuilA, 2-10mg of levamisole, 20-100mg of Chinese herbal polysaccharide, and phosphate buffer saline for the rest.

[0039] The above-mentioned Chinese herbal medicine polysaccharide is selected from lentinan or astragalus polysaccharide or wolfberry polysaccharide or privet fruit polysaccharide.

[0040] The preparation method of the vaccine adjuvant of the present invention comprises: first preparing a high-concentration mother solution, then preparing a low-concentration adjuvant solution, and finally diluting it to the required concentrati...

Embodiment 3

[0060] The preparation of embodiment 3 adjuvanted mycoplasma pneumonia live vaccine

[0061] Complete the vaccine adjuvant prepared by the method described in Example 2, the volume ratio of live vaccine and vaccine adjuvant is 1: 1~1: 5 according to the ratio of preparing and mixing to be the adjuvanted Mycoplasma suis Pneumonia Live Vaccine. The preferred volume ratio of the live vaccine against Mycoplasma pneumoniae of swine to the vaccine adjuvant is 1:2-1:3. After being mixed, the live vaccine of mycoplasma pneumoniae containing adjuvant can be improved from intrapulmonary injection immunity to intramuscular injection immunity.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a vaccine adjuvant of swine mycoplasmal pneumonia live vaccine, which is mainly prepared from an ISCOM substrate, levamisole, traditional Chinese herbal polysaccharide and phosphate buffer. Each ml of adjuvant contains 0.1 to 2mg of Quil A in the ISCOM substrate, 2 to 10mg of levamisole, 20 to 100mg of traditional Chinese herbal polysaccharide and the balance of phosphate buffer. The combination of the ISCOM substrate, the levamisole and the traditional Chinese herbal polysaccharide can well make the best of respective advantages and complement each other, so that the adjuvant can strengthen the immune stimulating ability of the swine mycoplasmal pneumonia live vaccine and strengthen the immune effect of the vaccine, and has the advantages of simple and convenient preparation method, stable performance, convenient mass production and the like. When the vaccine adjuvant is applied, intramuscular injection immunization can be performed by blending a proper proportion of swine mycoplasmal pneumonia live vaccine and the adjuvant of the invention; the intramuscular injection immunization of the swine mycoplasmal pneumonia live vaccine is realized; and the defects of the traditional intrapulmonary injection immunization are overcome.

Description

technical field [0001] The invention relates to a vaccine adjuvant, in particular to a vaccine adjuvant which has no toxicity to live vaccine of swine mycoplasma pneumoniae and can specifically enhance its immune stimulating ability. Background technique [0002] Mycoplasma hyopneumoniae (Mhp) is the main pathogen of swine enzootic pneumonia and swine asthma. The disease caused by Mycoplasma hyopneumoniae alone is called Mycoplasma Pneumoniae of Swine (MPS), and the main symptoms are cough and wheezing. The disease mainly causes the feed conversion rate and growth retardation of pigs, with high morbidity and low mortality. Mycoplasma suis pneumonia is widely prevalent in the world, causing significant economic losses to the modern pig industry. [0003] Mycoplasma swine pneumonia is a stubborn chronic infectious disease, the effect of drug treatment is not satisfactory, and it is easy to relapse after stopping the drug. Once the disease is prevalent in pig farms, it is dif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/39A61K39/02A61P11/00A61P31/04
Inventor 熊祺琰邵国青张道华冯志新刘茂军
Owner JIANGSU ACAD OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com